{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:50:44Z","timestamp":1792785044876,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The work was supported by the Department of Medicine, University of Missouri, Columbia, USA.","id":[{"id":"https:\/\/ror.org\/02ymw8z06","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-57571-6","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T06:23:45Z","timestamp":1782541425000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Stabilization of HIF-1\u03b1 using the prolyl hydroxylase inhibitor roxadustat reduces gastrointestinal graft-versus-host disease"],"prefix":"10.1038","volume":"16","author":[{"given":"Vasantharaja","family":"Raguraman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanid","family":"Mohiyuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Plank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Benge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linnea","family":"Banker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Hammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senthilnathan","family":"Palaniyandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard C.","family":"Hildebrandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"key":"57571_CR1","doi-asserted-by":"crossref","unstructured":"Passweg, J. R. et al. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplantation 2021 56:7 56, 1651\u20131664 (2021).","DOI":"10.1038\/s41409-021-01227-8"},{"key":"57571_CR2","doi-asserted-by":"publisher","unstructured":"Ghimire, S. et al. Pathophysiology of GvHD and other HSCT-related major complications. Frontiers in Immunology vol. 8 Preprint at (2017). https:\/\/doi.org\/10.3389\/fimmu.2017.00079","DOI":"10.3389\/fimmu.2017.00079"},{"key":"57571_CR3","doi-asserted-by":"crossref","unstructured":"Holtan, S. G. et al. Disease progression, treatments, hospitalization, and clinical outcomes in acute GVHD: a multicenter chart review. Bone Marrow Transplantation 2022 57:10 57, 1581\u20131585 (2022).","DOI":"10.1038\/s41409-022-01764-w"},{"key":"57571_CR4","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2011-06-364265","volume":"119","author":"M Jagasia","year":"2012","unstructured":"Jagasia, M. et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 119, 296\u2013307 (2012).","journal-title":"Blood"},{"key":"57571_CR5","doi-asserted-by":"publisher","unstructured":"Vaillant, A. A. J., Modi, P. & Mohammadi, O. Graft-Versus-Host Disease. Transplantation Pancreas: Second Ed. 755\u2013763. https:\/\/doi.org\/10.1007\/978-3-031-20999-4_54 (2024).","DOI":"10.1007\/978-3-031-20999-4_54"},{"key":"57571_CR6","doi-asserted-by":"publisher","first-page":"224274","DOI":"10.3389\/fimmu.2017.00079","volume":"8","author":"S Ghimire","year":"2017","unstructured":"Ghimire, S. et al. Pathophysiology of GvHD and other HSCT-related major complications. Front. Immunol. 8, 224274 (2017).","journal-title":"Front. Immunol."},{"key":"57571_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-230X-11-109","volume":"11","author":"R Noth","year":"2011","unstructured":"Noth, R. et al. Increased intestinal permeability and tight junction disruption by altered expression and localization of occludin in a murine graft versus host disease model. BMC Gastroenterol. 11, 1\u20139 (2011).","journal-title":"BMC Gastroenterol."},{"key":"57571_CR8","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1172\/JCI98554","volume":"129","author":"SC Nalle","year":"2019","unstructured":"Nalle, S. C. et al. Graft-versus-host disease propagation depends on increased intestinal epithelial tight junction permeability. J. Clin. Invest. 129, 902\u2013914 (2019).","journal-title":"J. Clin. Invest."},{"key":"57571_CR9","first-page":"51","volume":"80","author":"JE Ziello","year":"2007","unstructured":"Ziello, J. E., Jovin, I. S. & Huang, Y. Hypoxia-Inducible Factor (HIF)-1 Regulatory Pathway and its Potential for Therapeutic Intervention in Malignancy and Ischemia. Yale J. Biol. Med. 80, 51 (2007).","journal-title":"Yale J. Biol. Med."},{"key":"57571_CR10","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1093\/ecco-jcc\/jjac092","volume":"16","author":"S Bhat","year":"2022","unstructured":"Bhat, S. & Rieder, F. Hypoxia-Inducible Factor 1-Alpha Stabilizers in the Treatment of Inflammatory Bowel Diseases: Oxygen as a Novel IBD Therapy? J. Crohns Colitis. 16, 1924 (2022).","journal-title":"J. Crohns Colitis"},{"key":"57571_CR11","doi-asserted-by":"crossref","unstructured":"Van Welden, S., Selfridge, A. C. & Hindryckx, P. Intestinal hypoxia and hypoxia-induced signalling as therapeutic targets for IBD. Nature Reviews Gastroenterology & Hepatology 2017 14:10 14, 596\u2013611 (2017).","DOI":"10.1038\/nrgastro.2017.101"},{"key":"57571_CR12","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S0092-8674(03)00154-5","volume":"112","author":"T Cramer","year":"2003","unstructured":"Cramer, T. et al. HIF-1\u03b1 Is Essential for Myeloid Cell-Mediated Inflammation. Cell 112, 645\u2013657 (2003).","journal-title":"Cell"},{"key":"57571_CR13","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1172\/JCI200421086","volume":"114","author":"J Karhausen","year":"2004","unstructured":"Karhausen, J. et al. Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. J. Clin. Invest. 114, 1098\u20131106 (2004).","journal-title":"J. Clin. Invest."},{"key":"57571_CR14","doi-asserted-by":"publisher","first-page":"6306","DOI":"10.4049\/jimmunol.1002541","volume":"185","author":"P Hindryckx","year":"2010","unstructured":"Hindryckx, P. et al. Hydroxylase Inhibition Abrogates TNF-\u03b1\u2013Induced Intestinal Epithelial Damage by Hypoxia-Inducible Factor-1\u2013Dependent Repression of FADD. J. Immunol. 185, 6306\u20136316 (2010).","journal-title":"J. Immunol."},{"key":"57571_CR15","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1097\/TP.0000000000003383","volume":"104","author":"S Palaniyandi","year":"2020","unstructured":"Palaniyandi, S. et al. The Prolyl Hydroxylase Inhibitor Dimethyl Oxalyl Glycine Decreases Early Gastrointestinal GVHD in Experimental Allogeneic Hematopoietic Cell Transplantation. Transplantation 104, 2507\u20132515 (2020).","journal-title":"Transplantation"},{"key":"57571_CR16","doi-asserted-by":"publisher","first-page":"103506","DOI":"10.1016\/j.resp.2020.103506","volume":"281","author":"F Han","year":"2020","unstructured":"Han, F. et al. Hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat (FG-4592) alleviates sepsis-induced acute lung injury. Respir Physiol. Neurobiol. 281, 103506 (2020).","journal-title":"Respir Physiol. Neurobiol."},{"key":"57571_CR17","doi-asserted-by":"publisher","first-page":"971795","DOI":"10.3389\/fphar.2022.971795","volume":"13","author":"X Zhu","year":"2022","unstructured":"Zhu, X., Jiang, L., Wei, X., Long, M. & Du, Y. Roxadustat: Not just for anemia. Front. Pharmacol. 13, 971795 (2022).","journal-title":"Front. Pharmacol."},{"key":"57571_CR18","doi-asserted-by":"publisher","first-page":"130548","DOI":"10.1016\/j.bbagen.2023.130548","volume":"1868","author":"G Kong","year":"2024","unstructured":"Kong, G. et al. Roxadustat ameliorates experimental colitis in mice by regulating macrophage polarization through increasing HIF level. Biochim. et Biophys. Acta (BBA) - Gen. Subj. 1868, 130548 (2024).","journal-title":"Biochim. et Biophys. Acta (BBA) - Gen. Subj."},{"key":"57571_CR19","doi-asserted-by":"publisher","first-page":"110585","DOI":"10.1016\/j.ygeno.2023.110585","volume":"115","author":"Z Feng","year":"2023","unstructured":"Feng, Z. et al. Roxadustat protect mice from DSS-induced colitis in vivo by up-regulation of TLR4. Genomics 115, 110585 (2023).","journal-title":"Genomics"},{"key":"57571_CR20","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1182\/blood.V88.8.3230.bloodjournal8883230","volume":"88","author":"KR Cooke","year":"1996","unstructured":"Cooke, K. R. et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood 88, 3230\u20133239 (1996).","journal-title":"Blood"},{"key":"57571_CR21","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1172\/JCI3132","volume":"102","author":"GR Hill","year":"1998","unstructured":"Hill, G. R. et al. Interleukin-11 promotes T cell polarization and prevents acute graff- versus-host disease after allogeneic bone marrow transplantation. J. Clin. Invest. 102, 115\u2013123 (1998).","journal-title":"J. Clin. Invest."},{"key":"57571_CR22","doi-asserted-by":"crossref","unstructured":"Zhang, X., Goncalves, R. & Mosser, D. M. The isolation and characterization of murine macrophages. Curr Protoc. Immunol. Chapter 14, (2008).","DOI":"10.1002\/0471142735.im1401s83"},{"key":"57571_CR23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.bbmt.2014.09.025","volume":"21","author":"SV Radhakrishnan","year":"2015","unstructured":"Radhakrishnan, S. V. et al. Preventive Azithromycin Treatment Reduces Noninfectious Lung Injury and Acute Graft-versus-Host Disease in a Murine Model of Allogeneic Hematopoietic Cell Transplantation. Biol. Blood Marrow Transplant. 21, 30\u201338 (2015).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"57571_CR24","doi-asserted-by":"crossref","unstructured":"Cummins, E. P. et al. The hydroxylase inhibitor dimethyloxalylglycine is protective in a murine model of colitis. Gastroenterology 134, (2008).","DOI":"10.1053\/j.gastro.2007.10.012"},{"key":"57571_CR25","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1182\/blood.V90.8.3204","volume":"90","author":"GR Hill","year":"1997","unstructured":"Hill, G. R. et al. Total Body Irradiation and Acute Graft-Versus-Host Disease: The Role of Gastrointestinal Damage and Inflammatory Cytokines. Blood 90, 3204\u20133213 (1997).","journal-title":"Blood"},{"key":"57571_CR26","doi-asserted-by":"crossref","unstructured":"Chen, R., Ahmed, M. A. & Forsyth, N. R. Dimethyloxalylglycine (DMOG), a Hypoxia Mimetic Agent, Does Not Replicate a Rat Pheochromocytoma (PC12) Cell Biological Response to Reduced Oxygen Culture. Biomolecules 12, 541 (2022).","DOI":"10.3390\/biom12040541"},{"key":"57571_CR27","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMra1609337","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser, R. & Blazar, B. R. Acute Graft-versus-Host Disease \u2014 Biologic Process, Prevention, and Therapy. N. Engl. J. Med. 377, 2167\u20132179 (2017).","journal-title":"N. Engl. J. Med."},{"key":"57571_CR28","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1182\/blood-2006-10-054510","volume":"110","author":"C Borsotti","year":"2007","unstructured":"Borsotti, C. et al. Absence of donor T-cell\u2013derived soluble TNF decreases graft-versus-host disease without impairing graft-versus-tumor activity. Blood 110, 783\u2013786 (2007).","journal-title":"Blood"},{"key":"57571_CR29","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1242\/dmm.006668","volume":"4","author":"MA Schroeder","year":"2011","unstructured":"Schroeder, M. A. & DiPersio, J. F. Mouse models of graft-versus-host disease: advances and limitations. Dis. Model. Mech. 4, 318\u2013333 (2011).","journal-title":"Dis. Model. Mech."},{"key":"57571_CR30","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S1542-3565(04)00011-4","volume":"2","author":"DH Fowler","year":"2004","unstructured":"Fowler, D. H. et al. Clinical cytokine storm as revealed by monocyte intracellular flow cytometry: correlation of tumor necrosis factor \u03b1 with severe gut graft-versus-host disease. Clin. Gastroenterol. Hepatol. 2, 237\u2013245 (2004).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"57571_CR31","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s12185-011-0803-1","volume":"93","author":"JE Levine","year":"2011","unstructured":"Levine, J. E. IMPLICATIONS OF TNF-\u03b1 IN THE PATHOGENESIS AND MANAGEMENT OF GVHD. Int. J. Hematol. 93, 571 (2011).","journal-title":"Int. J. Hematol."},{"key":"57571_CR32","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/S1083-8791(03)00087-9","volume":"9","author":"R Korngold","year":"2003","unstructured":"Korngold, R., Marini, J. C., de Baca, M. E., Murphy, G. F. & Giles-Komar, J. Role of tumor necrosis factor-\u03b1 in graft-versus-host disease and graft-versus-leukemia responses. Biol. Blood Marrow Transplant. 9, 292\u2013303 (2003).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"57571_CR33","doi-asserted-by":"publisher","first-page":"77819","DOI":"10.18632\/oncotarget.20836","volume":"8","author":"E Panisova","year":"2017","unstructured":"Panisova, E. et al. Lactate stimulates CA IX expression in normoxic cancer cells. Oncotarget 8, 77819 (2017).","journal-title":"Oncotarget"},{"key":"57571_CR34","doi-asserted-by":"publisher","first-page":"24204","DOI":"10.1074\/jbc.M109.006510","volume":"284","author":"T van den Beucken","year":"2009","unstructured":"van den Beucken, T. et al. Hypoxia-induced Expression of Carbonic Anhydrase 9 Is Dependent on the Unfolded Protein Response. J. Biol. Chem. 284, 24204 (2009).","journal-title":"J. Biol. Chem."},{"key":"57571_CR35","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1093\/jimmun\/vkaf167","volume":"214","author":"A Wrobeln","year":"2025","unstructured":"Wrobeln, A. et al. Roxadustat enhances inflammation and metabolic reprogramming in human leukocytes by affecting oxygen sensing. J. Immunol. 214, 3321\u20133331 (2025).","journal-title":"J. Immunol."},{"key":"57571_CR36","doi-asserted-by":"crossref","unstructured":"Kuo, W. T. et al. The Tight Junction Protein ZO-1 Is Dispensable for Barrier Function but Critical for Effective Mucosal Repair. Gastroenterology 161, 1924\u20131939 (2021).","DOI":"10.1053\/j.gastro.2021.08.047"},{"key":"57571_CR37","doi-asserted-by":"publisher","first-page":"3775","DOI":"10.3390\/cells11233775","volume":"11","author":"AJ Haas","year":"2022","unstructured":"Haas, A. J. et al. ZO-1 Guides Tight Junction Assembly and Epithelial Morphogenesis via Cytoskeletal Tension-Dependent and -Independent Functions. Cells 11, 3775 (2022).","journal-title":"Cells"},{"key":"57571_CR38","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/nyas.14798","volume":"1514","author":"WT Kuo","year":"2022","unstructured":"Kuo, W. T., Odenwald, M. A., Turner, J. R. & Zuo, L. Tight junction proteins occludin and ZO-1 as regulators of epithelial proliferation and survival. Ann. N Y Acad. Sci. 1514, 21\u201333 (2022).","journal-title":"Ann. N Y Acad. Sci."},{"key":"57571_CR39","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.3324\/haematol.2020.253716","volume":"106","author":"S Cordes","year":"2021","unstructured":"Cordes, S. et al. Endothelial damage and dysfunction in acute graft-versus-host disease. Haematologica 106, 2147\u20132160 (2021).","journal-title":"Haematologica"},{"key":"57571_CR40","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1128\/MCB.06029-11","volume":"32","author":"PM Cummins","year":"2012","unstructured":"Cummins, P. M. & Occludin One Protein, Many Forms. Mol. Cell. Biol. 32, 242\u2013250 (2012).","journal-title":"Mol. Cell. Biol."},{"key":"57571_CR41","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/ajg.2009.700","volume":"105","author":"M Co\u00ebffier","year":"2010","unstructured":"Co\u00ebffier, M. et al. Increased proteasome-mediated degradation of occludin in irritable bowel syndrome. Am. J. Gastroenterol. 105, 1181\u20131188 (2010).","journal-title":"Am. J. Gastroenterol."},{"key":"57571_CR42","doi-asserted-by":"publisher","first-page":"7210","DOI":"10.2741\/3223","volume":"13","author":"R Rao","year":"2008","unstructured":"Rao, R. Oxidative stress-induced disruption of epithelial and endothelial tight junctions. Front. Biosci. 13, 7210\u20137226 (2008).","journal-title":"Front. Biosci."},{"key":"57571_CR43","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/nm.3517","volume":"20","author":"L Schwab","year":"2014","unstructured":"Schwab, L. et al. Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage. Nat. Med. 20, 648\u2013654 (2014).","journal-title":"Nat. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57571-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57571-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57571-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:02:25Z","timestamp":1790395345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57571-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["57571"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-57571-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"assertion":[{"value":"24 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"GCH and SP have received preclinical research funding from Aceta Pharma and Incyte. GCH has advisory roles in the field of GVHD with Incyte. Stocks from Pfizer, Kite Pharma, Incyte, Jazz Pharmaceuticals, Morphosys, Alexion Pharmaceuticals, Daichiy, Karyopharm Therapeutics, Seattle Genetics, Jannsen Pharmaceuticals, RAPA Therapeutics, Ono Pharmaceutical, AstraZeneca, and CTI BioPharma Corp. Other authors declare no conflict of interest. This manuscript has been approved by all authors.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experimental protocols were approved by the Institutional Animal Care and Use Committee (ACUC) of the University of Kentucky and Institutional ACUC committee of the University of Missouri (Approved Protocol 38123), and all methods were carried out in accordance with relevant institutional guidelines and regulations.","order":2,"name":"Ethics","label":"Ethics declarations","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors take full responsibility for the content of this publication, and no AI tool was used to write this manuscript.","order":3,"name":"Ethics","label":"Declaration of generative AI and AI-assisted technologies in the manuscript preparation process","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"29558"}}